Key Financial Data Of Reporting Company

Delta-Fly Pharma, Inc. - Filing #7296920

Concept 2024-04-01 to
2024-09-30
As at
2024-09-30
As at
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2023-09-30
As at
2023-09-30
Key financial data of reporting company
Business results of reporting company
Ordinary profit (loss)
-915,896,000 JPY
-1,426,891,000 JPY
-599,036,000 JPY
Profit (loss)
-917,147,000 JPY
-1,429,393,000 JPY
-600,287,000 JPY
Equity in earnings (losses) of affiliates if equity method is applied
JPY
JPY
JPY
Share capital
4,731,185,000 JPY
4,731,185,000 JPY
3,901,415,000 JPY
Total number of issued shares
8,229,900 xbrli:shares
8,229,900 xbrli:shares
6,544,600 xbrli:shares
Net assets
315,508,000 JPY
1,232,656,000 JPY
402,835,000 JPY
Total assets
425,820,000 JPY
1,474,155,000 JPY
490,779,000 JPY
Dividend paid per share
Basic earnings (loss) per share
-111.44
-198.78
-91.92
Diluted earnings per share
Equity-to-asset ratio
0.739 xbrli:pure
0.836 xbrli:pure
0.818 xbrli:pure
Net cash provided by (used in) operating activities
-1,066,826,000 JPY
-1,279,615,000 JPY
-619,048,000 JPY
Net cash provided by (used in) investing activities
JPY
207,000 JPY
918,000 JPY
Net cash provided by (used in) financing activities
JPY
1,853,195,000 JPY
211,138,000 JPY
Cash and cash equivalents
349,122,000 JPY
1,417,062,000 JPY
436,811,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.